Discovery of Novel Imidazo[1,2- a ]pyridine-Based HDAC6 Inhibitors as an Anticarcinogen with a Cardioprotective Effect
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c01168 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Fei-Fei Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Esophageal Cancer Prevention and Treatment; Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of Ch…. Hauptthemen laut MEDLINE: Pyridines, Histone Deacetylase Inhibitors, Histone Deacetylase 6, Cardiotonic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Natural Science Foundation of Henan Province, China Postdoctoral Science Foundation, Science and Technology Innovation Talents in Universities of Henan Province.
Abstract (Originalsprache)
Cardiotoxicity associated with chemotherapy has gradually become the major cause of death in cancer patients. The development of bifunctional drugs with both cardioprotective and antitumor effects has become the future direction. HDAC6 plays important roles in the progression, treatment, and prognosis of cancer and cardiovascular diseases, but bifunctional inhibitors have not been reported. Herein, structure-activity relationship studies driven by pharmacophore-based remodification and fragment-based design were performed to yield highly potent HDAC6 inhibitor I-c4 containing imidazo[1,2-a]pyridine. Importantly, I-c4 effectively suppressed the growth of MGC-803 xenografts in vitro and in vivo by inhibiting the deacetylation pathway without causing myocardial damage after long-term administration. Meanwhile, I-c4 could mitigate severe myocardial damage against H2O2 or myocardial ischemia/reperfusion in vitro and in vivo. Further studies revealed that the cardioprotective effect of I-c4 was associated with reduction of inflammatory cytokines. Taken together, I-c4 may represent a novel lead compound for further development of an anticarcinogen with a cardioprotective effect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Esophageal Cancer Prevention and Treatment; Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China; School of Pharmaceutical Science and Institute of Pharmaceutical…
- School of Pharmacy, Henan University of Traditional Chinese Medicine, Zhengzhou 450046, China.
- China Meheco Topfond Pharmaceutical Co.; Key Laboratory of Cardio-cerebrovascular Drug, Zhumadian 463000, China.
ORCID-Profile: Li-Ying Ma
Förderung
- Natural Science Foundation of Henan Province
- China Postdoctoral Science Foundation
- Science and Technology Innovation Talents in Universities of Henan Province
- National Natural Science Foundation of China
- Joint Fund for Science and Technology Research and Development Plan of Henan province
Zitieren
APA
Yang, F. F., Liu, J. J., Xu, X. L., Hu, T., Liu, J. Q., He, Z. X., Zhao, G. Y., Wei, B., & Ma, L. Y. (2024). Discovery of Novel Imidazo[1,2- a ]pyridine-Based HDAC6 Inhibitors as an Anticarcinogen with a Cardioprotective Effect. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01168
Vancouver
Yang FF, Liu JJ, Xu XL, Hu T, Liu JQ, He ZX, et al. Discovery of Novel Imidazo[1,2- a ]pyridine-Based HDAC6 Inhibitors as an Anticarcinogen with a Cardioprotective Effect. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01168
BibTeX
@article{Yang2024,
author = {Yang, Fei-Fei and Liu, Jing-Jing and Xu, Xue-Li and Hu, Ting and Liu, Jian-Quan and He, Zhang-Xu and Zhao, Guang-Yuan and Wei, Bo and Ma, Li-Ying},
title = {Discovery of Novel Imidazo[1,2- a ]pyridine-Based HDAC6 Inhibitors as an Anticarcinogen with a Cardioprotective Effect},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c01168}
}
EUVIMED